Naturally occurring catalytic antibodies: Evidence for preferred development of the catalytic function in IgA class antibodies

Department of Pathology and Laboratory Medicine, Chemical Immunology Research Center, University of Texas - Houston Medical School, 6431 Fannin, Houston, TX 77030, USA.
Molecular Biotechnology (Impact Factor: 1.88). 07/2007; 36(2):113-22. DOI: 10.1007/s12033-007-0003-7
Source: PubMed


IgG class antibodies express catalytic activities rarely and at very low levels. Here, we studied polyclonal IgA and IgG preparations from healthy human sera and saliva for the ability to hydrolyze model peptidyl-aminomethylcoumarin (peptide-AMC) substrates. These substrates permit objective evaluation of the catalytic potential of the antibody classes with minimal effects of noncovalent interactions occurring at sites remote from the reaction center. The IgA preparations hydrolyzed Glu-Ala-Arg-AMC at rates 3-orders of magnitude greater than IgG preparations from the same individuals. The cleavage occurred preferentially on the C terminal side of a basic residue. The activity was confirmed using monoclonal IgAs isolated from patients with multiple myeloma. Active site-directed inhibitors of serine proteases inhibited the catalytic activity and were bound irreversibly by the IgA, suggesting the involvement of a serine protease-like mechanism similar to that utilized by previously described IgM antibodies. These observations suggest that mechanisms underlying B cell clonal selection favor the retention and improvement of catalytic activity in the IgA, but not the IgG compartment of the immune response.

Download full-text


Available from: Sudhir Paul,
9 Reads
  • Source
    • "Even sub- Angstrom disturbances in catalytic site topography result in abruptly altered catalytic activity. IgMs and IgAs consistently display superior catalytic activity compared to IgG class antibodies (Mitsuda et al., 2007). (c) Full-length antibodies display superior stability in vivo. "

    eLS, 01/2006; , ISBN: 9780470015902
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antibody hydrolysis of the superantigenic gp120 site and HIV-1 neutralization was studied as a potential anti-HIV mechanism in uninfected humans. gp120 hydrolysis by purified serum and salivary antibodies was determined by electrophoresis and peptide sequencing, the proteolytic mechanism was analyzed using electrophilic peptide analogs, and viral neutralization was studied using peripheral blood mononuclear cells as hosts. Polyclonal and monoclonal IgA but not IgG preparations selectively catalyzed the cleavage of HIV gp120 at rates sufficient to predict biologically relevant protection against the virus. The IgA hydrolytic reaction proceeded by noncovalent recognition of gp120 residues 421-433, a component of the superantigenic site of gp120, coordinated with peptide bond cleavage via a serine protease-like mechanism. The Lys-432-Ala-433 bond was one of the cleavage sites. Infection of peripheral blood mononuclear cells by a primary isolate of HIV was neutralized by the IgA but not IgG fractions. The neutralizing activity was specifically inhibited by an electrophilic inhibitor of the catalytic activity. The existence of catalytic IgAs to gp120 in uninfected humans suggests their role in resistance to HIV.
    AIDS Research and Human Retroviruses 01/2008; 23(12):1541-54. DOI:10.1089/aid.2007.0081 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Catalytic activity of certain antibodies was proposed by Linus Pauling for the very first time more than six decades ago. Since then few examples of catalytic antibodies (abzymes) were found in human organism. From late 80's many synthetic abzymes were obtained after immunization by Transition State Analogs (TSA). Another approach is based on functional mimicry of antibody to an active site of an enzyme. Detection of an abzymatic activity requires special immunoassays. This unique strategy can be employed for new methods of drug synthesis, as well as for in vivo therapies. Catalytic antibodies seem to be a promising tool for therapeutic purposes, because of their specifity and stereoselectivity.
    Current Medicinal Chemistry 02/2008; 15(16):1606-15. DOI:10.2174/092986708784911533 · 3.85 Impact Factor
Show more